Introduction

Triple-negative breast cancer (TNBC), defined immuno-histologically by the absence of estrogen (ER), progesterone (PR), and HER2 receptors, is a heterogeneous entity comprising subtypes with distinct clinical and molecular features [1–4]. Despite some variability in clinical course, the prognosis of TNBC patients is poorer overall than those with stage-equivalent non-TNBC [5–7].

The advent of high-throughput sequencing technologies and bioinformatics has improved our understanding of the molecular diversity of TNBC and opened new avenues for potential targeted therapeutic strategies [2, 3, 8]. Differential response to neoadjuvant chemotherapy among molecular subtypes of TNBC has been reported [9]; yet, prospective validation of molecular subtyping as a predictive tool in TNBC is currently lacking. In addition, targeted agents investigated by our group and others have not yielded convincing activity in unselected patients, highlighting an unmet need for novel therapeutic strategies in TNBC (reviewed in [10]).

The identification of breast cancer cells with self-renewal and multilineage differentiation capacity led to the hypothesis that tumor growth and heterogeneity are driven by subpopulations of breast cancer stem cells (BCSCs) [11, 12]. Cellular markers, CD44+/CD24−/low phenotype [11] and aldehyde dehydrogenase 1 (ALDH1) activity [12] along with functional assays, such as anchorage-independent growth and mammosphere formation, are commonly used to isolate tumor subpopulations enriched for BCSCs [13, 14]. Notwithstanding, the exact molecular features of this putative tumor cell subset currently remain undefined.

Because of their intrinsic chemoresistance [15, 16] and propensity for invasion and metastasis [17, 18], it has been suggested that enrichment for BCSCs is associated with aggressive tumor biology and poor clinical outcome [12, 19–21]. A corollary to this premise is that enrichment for BCSC subpopulations in claudin-low [22], metaplastic [23], and some basal-like TNBC [24] may partly explain their aggressive clinical course and poor prognosis [25, 26]. In this respect, enrichment for BCSC phenotype and genetic signature in TNBC was shown to negatively...
correlate with pathologic complete response [26] and has been associated with higher incidence of recurrence and metastasis [27].

Deregulation of receptor tyrosine kinase (RTK), TGF-β signaling and embryonic pathways, Wnt, Hedgehog (Hh), and Notch have been recognized as key signaling events driving tumorigenesis in BCSCs [28–32]. The Hh pathway plays a key role in embryonic development and regulates stem cell renewal and tissue homeostasis [33–36]. Its role as an oncogenic pathway in basal cell carcinoma and medulloblastoma is well established [37, 38]. A growing body of literature substantiates the role of deregulated Hh signaling in breast cancer [39–41] with emerging data also highlighting its pivotal contribution to TNBC pathophysiology [42–46].

Herein, we review the evidence supporting a pathogenic role for Hh signaling in TNBC. We also discuss mechanisms of Hh pathway activation highlighting the critical contribution of extrinsic mediators and other key oncogenic pathways to deregulated Hh signaling in TNBC. Insight into these mechanisms and their potential implication in bypass signaling promoting resistance to Hh inhibitors is crucial for the design of effective Hh- and BCSC-targeted therapeutic strategies in TNBC.

Hedgehog Signaling and Regulation

The hedgehog signaling cascade

The Hh pathway plays an essential role in embryonic patterning and is involved in stem cell renewal, tissue regeneration, and repair [33–36]. It involves a signaling cascade mediated by three secreted ligands—Sonic Hedgehog (SHH), Indian Hedgehog (IHH), and Desert Hedgehog (DHH)—and transmembrane receptor and co-receptor Patched (PTCH) and SMO, respectively (Fig. 1). Proper Hh signaling is also dependent on the presence of an intact primary cilium, a microtubule-containing organelle projecting from the cell surface; its disruption abrogates the signaling cascade (reviewed in [47]).

Three glioma-associated oncogene (GLI) transcription factors, GLI1, GLI2, and GLI3, are the effectors of Hh signaling and regulate the expression of the pathway target genes [48, 49]. GLI2 and GLI3 contain both activation and repression domains and can function as full-length transcriptional activators (GLI1A) or as truncated repressors (GLI1R), whereas GLI1, lacking a repression domain, exists only as a full-length transcriptional activator (GLI1A) [50].

GLI2A and GLI3R are considered to be the primary transcriptional activator and repressor of Hh signaling during embryogenesis, respectively; conversely, GLI1A is dispensable for development [51, 52]. GLI3R-mediated suppression of Hh target gene transcription is a critical event for mammary bud formation [53]. Repression of the Hh pathway, as evidenced by the lack of transcriptional reporters of positive Hh signaling, is also required for proper embryonic and post-natal mammary gland development [53]. Therefore, during normal development, GLI1 expression is absent and GLI2 activity antagonized by GLI3R in the mammary gland parenchyma [53].

In contrast, GLI1 and GLI2 are considered to be the main oncogenic effectors of Hh signaling, with lack of data supporting the contribution of GLI3 to breast carcinogenesis [39, 40, 42–45, 54–56]. To date, numerous GLI1 and GLI2 targets, involved in cell proliferation and survival, EMT, invasion, migration, angiogenesis, osteolytic metastases and drug resistance, have been identified (Table 1).

Regulation of hedgehog signaling

The GLI-driven transcriptional program is modulated by intrinsic and extrinsic regulation of GLI activity through post-translational modification, such as phosphorylation, ubiquitin-mediated degradation, acetylation, as well as regulation of nucleocyttoplasmic shuttling (reviewed in [57]). GLI phosphorylation by kinases—Protein kinase A (PKA), glycogen synthase kinase-3beta (GSK3β), and casein kinase 1 (CK1)—creates binding sites for adaptor protein Beta-transducin repeat containing E3 ubiquitin protein ligase (β-TrCP), and marks GLI proteins for ubiquitin-mediated proteasomal degradation or processing into repressor forms [58, 59]. Another intrinsic regulatory mechanism involves GLI acetylation which interferes with the transcriptional activity of GLI1 and GLI2 by preventing their recruitment onto their target gene promoters [60, 61]. Conversely, GLI1 and GLI2 deacetylation by Class I histone deacetylases (HDAC) enhances their transcriptional activity [60, 61].

Extrinsic regulation of Hh signaling by oncogenic pathways, such as RAS/MAPK, PI3K, and TGF-β signaling, occurs through modulation of the expression or activity of Hh pathway components, predominantly GLI proteins. For instance, oncogenic and nonmutated aberrant RAS signaling enhance GLI1 function in pancreatic, gastric, and breast cancer through various mechanisms, including potentiation of its transcriptional activity and nuclear translocation, inhibition of its cytoplasmic sequestration by SUFU and proteasome-mediated degradation [43, 62–64].

PI3K signaling also interferes with proteasomal GLI degradation by inhibiting PKA and GSK3β-activity [65] and increased GLI1 expression in response to activated PI3K signaling has been shown to confer tamoxifen resistance in ER-positive breast cancer [39]. In addition, upregulation of GLI1 and SHH expression mediated by NF-κB signaling has been reported in breast cancer [45, 66]. Likewise, increased
GLI2 expression in response to TGF-β/SMAD signaling occurs through transcriptional regulation and is independent of downstream RAS/MAPK or PI3K/AKT signaling [67].

**Canonical and Noncanonical Hedgehog Signaling**

Canonical Hh signaling has been defined as Hh ligand/receptor-induced signaling leading to GLI activation. No consensus exists, however, on the definition of noncanonical Hh signaling. Cellular responses to Hh ligand, mediated by either PTCH (type I) or SMO (type II) independent of GLI, are classically considered as noncanonical signaling mechanisms [68]. In addition, some have also included in this definition, mechanisms leading to GLI activation independent of Hh ligand-mediated signaling [69]. The definition we have adopted in this review comprises only type I or type II signaling, and we have referred to ligand/receptor-independent GLI1 activation as canonical ligand-independent signaling.
Hedgehog Pathway in TNBC

J. G. Habib & J. A. O'Shaughnessy

Table 1. Transcriptional targets of Hedgehog signaling.

| Hedgehog signaling target genes |
|---------------------------------|
| **Cell proliferation and survival** |
| CCM1 (cyclin D1)\(^1\) |
| BMI-1 (BMI1 polycomb ring finger oncogene) |
| P63 |
| FOXM1 (forkhead box M1)\(^1\) |
| BCL-2 (B-cell CLL/Lymphoma 2)\(^1\) |
| **EMT** |
| SNAI1 (snail family zinc finger 1) |
| FOXM1 |
| Mechanism: FOXM1-mediated upregulation of EMT transcription factor Slug by FOXM1 reported in TNBC |
| FOXC2\(^2\) (forkhead box C2 (MFH-1, mesenchyme forkhead 1)) |
| Mechanism not well understood in TNBC. Downregulation of the E-cadherin stabilizing protein p-120 catenin by FOXC2 has been described in non-small-cell lung cancer |
| **Invasion, migration, and angiogenesis** |
| VEGF (vascular endothelial growth factor A) |
| NRP2 (neuropilin 2) |
| CYR61 (cysteine-rich, angiogenic inducer, 61) |
| MMP (matrix metalloproteinase) 2, MMP 9, MMP 11 |
| FOXM1 via regulating the expression of extracellular matrix degrading factors uPA (urokinase plasminogen activator), uPAR (urokinase plasminogen activator receptor), MMP2, MMP 9 along with VEGF |
| CXCR4 (chemokine receptor 4) |
| **Osteolytic metastases** |
| PTHrP (parathyroid hormone-like hormone) |
| OPN (SSP1, secreted phosphoprotein 1) |
| **Chemotherapy resistance** |
| ABCB1 (ATP-binding cassette, subfamily B, member 1) |
| ABCG2 (ATP-binding cassette, subfamily G, member 2) |
| Anthracycline and taxane resistance. Mechanism: active drug efflux |
| FOXM1 |
| Anthracycline and cisplatin resistance. Mechanism: induction of double-stranded DNA repair gene expression |
| Taxane resistance |
| Mechanism: upregulation of the protein stathmin leading to microtubule disruption and interfering with paclitaxel microtubule binding |
| BMI-1 |
| Resistance to five fluorouracil (5-FU) |
| Mechanism: BMI-mediated inhibition of mitochondrial apoptotic pathways induced by 5-FU |

\(^1\)Established transcriptional targets in non-mammary cells/tumors.  
\(^2\)FOXC2 is the target Hh signaling and other developmental pathways.

Further classified as paracrine, autocrine or reverse paracrine, and ligand-independent signaling (Fig. 2).

Ligand-dependent autocrine signaling occurs when cancer cells are activated by their secreted Hh ligand [70, 71]. Ligand-dependent paracrine signaling, on the other hand, occurs when tumor cell secretion of Hh ligand does not activate the pathway in the secreting cells. Instead, Hh ligand diffuses locally and activates canonical signaling in surrounding cancer and/or stromal cells [72, 73]. Lastly, reverse paracrine signaling refers to activation of the pathway in cancer cells in response to stromal-derived Hh ligand [74].

Ligand-independent Hh signaling results in GLI activation independent of the presence of Hh ligand via mutational (loss of function PTCH mutations or activating SMO mutations) [37, 38, 75] or non-mutational mechanisms (GLI amplification or extrinsic potentiation of GLI transcriptional activity) [62–65, 76].

Current evidence suggests that Hh signaling in breast cancer overall, and TNBC specifically, is not mutation-driven; infrequent somatic mutations in SHH, PTCH, and GLI1 [77–79] have been reported; however, these findings have not been replicated in other studies [80, 81]. Instead, three primary mechanisms of Hh signaling have been described so far in TNBC. These include ligand-dependent paracrine and ligand-dependent autocrine signaling and non-mutational ligand-independent signaling mediated by oncogenic pathways along with key transcription factors and extracellular matrix proteins as discussed below.

Noncanonical Hedgehog signaling

Noncanonical Hh signaling mediated by PTCH (type I) has been shown to exert an antiapoptotic effect in non-mammary cells via disruption of proapoptotic DRAL-caspase activity or inhibition of H-Ras-induced apoptosis by modulation of tumor suppressor protein Tid1 [82, 83]. Recent studies have also outlined the role of PTCH-mediated noncanonical Hh signaling in regulating pubertal mammary ductal development [84, 85]. In murine models, activation of c-src, ERα, and downstream ERK1/2 signaling has been reported in mammary luminal epithelial cells in response to noncanonical PTCH-dependent Hh pathway activation [84–86]. Although the precise mechanism remains undefined, c-src and ERα signaling likely exert a mitogenic effect on luminal progenitor cells leading to mammary ductal elongation from terminal end buds at puberty [84, 85]. Despite evidence suggesting that similar noncanonical Hh signaling exists in non-tumorigenic human mammary epithelial cells, its role in carcinogenesis is currently unknown [84, 86].

SMO-dependent (type II) noncanonical Hh signaling promotes endothelial cell tubulogenesis, fibroblast and
non-mammary cancer cell migration by activation of small GTP-ases Rho and Rac1 [87–89]. Nonetheless, at the present time, the existence and potential role of this signaling mechanism in breast carcinogenesis has not been investigated.

**Hedgehog Signaling in Triple-Negative Breast Cancer**

**Hh signaling and cancer stem cell reprogramming**

Extensive preclinical data highlight the key contribution of Hh signaling in cancer stem cell reprogramming in TNBC [41–45, 55]. A causal role for Hh signaling in regulating the stem cell factor BMI-1 and conferring mammosphere-forming ability in vitro and tumor initiation in vivo has been reported [43]. Upregulation of GLI1 expression is characteristically observed in claudin-low breast cancer subtype mammospheres and tumors known to be highly enriched for BCSCs [43, 45]. Contrariwise, suppression of mammosphere formation and reduced ALDH1 activity in TNBC is noted upon Hh pathway inhibition [45, 90].

The role of Hh signaling in EMT regulation has been described in several malignancies including ovarian [91], prostate [92], pancreatic [93], and lung cancer [94] with evidence also supporting its contribution to EMT in TNBC [45, 55, 95]. Epithelial-mesenchymal transition (EMT) is a crucial process for stemness acquisition in carcinogenesis [28, 96]. It is a complex transdifferentiation process, orchestrated by several transcription factors (Zeb1/2, Snail1, Snail2 (Slug), Twist 1/2, Goosecoid, FOXM1, FOXC1, and FOXC2 among others) endowing breast tumor cells with enhanced self-renewal, tumor initiating capacity, invasiveness and resistance to apoptosis [26, 28, 96–98]. Hallmarks

---

**Figure 2.** Mechanisms of canonical Hedgehog signaling in cancer: (A) Ligand-dependent paracrine signaling, (B) Ligand-dependent autocrine signaling, (C) Ligand-dependent reverse paracrine signaling, (D) Ligand-independent signaling.
of EMT include loss of cell-adhesion marker expression, such as E-cadherin and claudins, and upregulation of mesenchymal markers such as vimentin and N-cadherin [99, 100].

Expression of mesenchymal markers and EMT transcription factors in TNBC cells is under direct regulation of Hh effector GLI1; abrogation of Hh signaling leads to loss of the mesenchymal phenotype and restores E-cadherin and epithelial marker keratin expression [55, 95]. In vivo studies in murine mammary glands with constitutive Hh signaling reveal prominent ductal hyperplasia and dysplasia caused by expansion of cell populations exhibiting basal cytokeratin, P63, and progenitor marker expression along with loss of basolateral polarity reminiscent of EMT [101, 102]. Moreover, the occurrence of ER-negative basal-like tumors characterized by loss of E-cadherin along with expression of progenitor markers in murine models with conditional GLI1 expression further corroborates the implication of the Hh pathway in EMT-mediated tumorigenesis [103]. Taken together, these data strongly suggest that establishment and maintenance of cancer stem cell phenotype in TNBC is orchestrated by Hh signaling.

**Hh signaling promotes tumor growth, invasion, metastasis, and drug resistance**

Preclinical studies provide strong evidence that deregulated Hh signaling confers a more aggressive tumor phenotype in TNBC. Activation of the Hh pathway enhances the proliferation, invasion, and migration of TNBC cells [44, 46]; conversely, its inhibition was shown to reduce their clonogenicity, self-renewal capacity, and motility [42, 45, 46, 104]. Increased angiogenesis [44] and expression of extracellular matrix degrading proteases [46, 105] are causative factors for the enhanced invasiveness and metastatic potential of TNBC cells observed upon Hh signaling activation.

An association between the Hh pathway and chemoresistance in TNBC has also been demonstrated. *In vitro* resistance to doxorubicin, paclitaxel, and cisplatin was shown to be mediated by GLI1 and was associated in TNBC cells with upregulation of multidrug resistance protein 1 (MDR1) and breast cancer resistance protein (BCRP), both transcriptional targets of Hh signaling ([55] Supplemental data). Increased expression of multidrug resistance efflux transporters may, therefore, provide potential explanation for the observed Hh-mediated survival and expansion of breast cancer cell subpopulations after taxane exposure [41].

*In vivo* data further lend support to the contribution of Hh signaling to aggressive tumor biology in TNBC, demonstrating enhanced local tumor invasion [56] with constitutive Hh signaling as well as increased incidence of visceral [44] and osteolytic metastases [54, 106]. Despite suggestive preclinical data, studies attempting to explore the clinical significance of deregulated Hh signaling in breast cancer are limited. In addition, most reports seeking to establish correlations between Hh pathway activation and tumor characteristics or clinical outcome have included all breast cancer subtypes with a limited number looking at subtype-specific associations. The ability to draw meaningful conclusions from these studies is further hampered by small sample size and the lack of uniform criteria or methodology used to define Hh signaling activation.

Keeping this in mind, a correlation between Hh signaling activation and high-grade, larger (≥T2), highly proliferative tumors and TNBC histology has been reported [56]. In TNBC, specifically, increased tumor GLI1 expression was found to correlate with higher tumor stage and node-positive disease [107]. More recently, Han et al. [90] have shown that enrichment for Hh pathway-associated genes is predictive of worse disease-free survival in breast cancer patients. Although the latter study included the largest number of clinical samples to date, it did not assess the prognostic significance of the Hh genetic signature in specific breast cancer subtypes.

**Mechanisms of deregulated Hh signaling in TNBC: interplay of ligand-independent and paracrine Hh signaling**

**Ligand-independent Hedgehog signaling**

TGF-β, RAS/MAPK signaling pathways, the extracellular matrix protein osteopontin (OPN), and transcription factors—NF-kB, FOXC1, and Hypoxia-induced factor (HIF)-1α—contribute to deregulated Hh signaling, thereby, leading to acquisition of the mesenchymal phenotype, enhanced growth, and invasion in TNBC [43, 45, 54, 55, 90, 95] (Fig. 3). GLI transcription factors are, nonetheless, the targets of these distinct pathways; thus, representing an integration nexus for their signaling inputs. In this setting, Hh-dependent gene transcription ensues independently of Hh ligand/receptor signaling activation [43, 54, 55].

Increased GLI2 expression and upregulation of its target gene PTH-rP, in response to TGF-β/SMAD signaling, plays a key role in the pathogenesis of osteolytic metastases in TNBC [54, 106]. Osteomimetic Runx2 expression augments GLI2-mediated PTH-rP upregulation and by promoting *IHH* transcription, it further potentiates the vicious cycle of tumor growth and osteolysis mediated by TGF-β/GLI2 [108]. VEGF Neuropilin 2 (NRP2) signaling in the triple-negative BCSC compartment was shown to directly activate GLI1 through integrin-mediated FAK signaling and downstream RAS/MAPK activation [43]. GLI1-mediated BCSC expansion was demonstrated in concert with increased expression of known
GLI1 transcriptional targets, VEGF and NRP2 in tumor cells, suggesting the existence of a positive feedback loop promoting Hh signaling deregulation and driving tumorigenesis in TNBC [43]. Hh pathway activation, underlying NF-kB and FOXC1-induced expansion of stem cell-like tumor cells in TNBC, also occurs in a ligand-independent fashion via direct potentiation of GLI1 expression and GLI2 activity, by NF-kB and FOXC1, respectively [45, 90]. Given these findings and taking into consideration the functional link between FOXC1 and NF-kB in TNBC [109], the existence of a critical tumorigenic network involving Hh signaling, FOXC1, and NF-kB cannot be excluded.

The tumor microenvironment is a key contributor to tumor growth and progression, and the importance of stromal signaling in regulating epithelial-mesenchymal plasticity in breast cancer cells is increasingly being recognized [110, 111]. Secretion of HIF-1α in response to tumor microenvironment hypoxia promotes the mesenchymal switch in TNBC cells via Hh signaling activation [95]. GLI1 appears to be the mediator of HIF-1α-Hh crosstalk and hypoxia-induced EMT. It is unclear, though, whether increased GLI1 expression in response to hypoxia involves direct regulation of GLI1 expression by HIF-1α downstream of SMO, as was reported in other cancers [93], or activation of other signaling factors, such as NF-kB, known to regulate both HIF-1α [112] and GLI1 expression in TNBC cells. The extracellular matrix protein OPN also modulates the epithelial-mesenchymal plasticity in TNBC cells by activating the Hh pathway downstream of SMO. In this respect, inactivation of GSK3β by OPN was shown to enhance the nuclear translocation and transcriptional activity of GLI1 [55]. Taking into consideration that OPN is a known GLI1 transcriptional target [113], a potential vicious cycle can be envisaged, amplifying OPN-mediated heterotypic signaling and expansion of stem cell-like tumor subpopulation in TNBC.

Peiris-Pagès et al. [114] recently proposed a model whereby exposure to cytotoxic drugs—doxorubicin, paclitaxel, and cisplatin, among others—induces metabolic and phenotypic

---

Figure 3. Hedgehog signaling activation in TNBC: interplay of ligand-dependent and ligand-independent mechanisms.
Hedgehog Pathway in TNBC

J. G. Habib & J. A. O’Shaughnessy

transformation of stromal fibroblasts leading to the emergence of a highly glycolytic, autophagic, and proinflammatory microenvironment. This catabolic microenvironment, in turn, was shown to promote activation of stemness pathways, including Hh signaling, in neighboring ER+ breast cancer cells [114]. Although this remains unsubstantiated, similar stromal signaling may conceivably partake in Hh signaling activation in TNBC cells following chemotherapy. Release of inflammatory cytokine after treatment with docetaxel was found to correlate with Hh signaling activation in a TNBC xenograft model of residual disease; thus, providing indirect evidence that inflammatory signaling induced by chemotherapy likely promote deregulated Hh signaling in tumor cells [115]. The exact mechanisms by which stromal-derived inflammatory signals lead to Hh signaling activation in tumor cells and their ligand- (and SMO-) dependence remain to be determined.

Paracrine Hedgehog signaling

Paracrine Hh signaling has been implicated in stromal-dependent tumor growth in breast cancer [56, 116] and a paracrine signature of high epithelial Hh ligand and high stromal GLI1 expression was found to be an independent predictor of decreased overall survival [56]. Preclinical data also lend support to the existence of similar paracrine signaling mechanisms in TNBC [56, 117, 118]. Hh ligand secreted by TNBC cells was shown to activate paracrine Hh signaling in neighboring bone marrow stromal cells promoting their release of pro-tumorigenic cytokines [117] and in osteoclasts precursors, thereby contributing to osteoclastogenesis and osteolysis [118]. In osteoclasts specifically, breast cancer-initiated paracrine Hh signaling is a critical event driving OPN and OPN-induced tissue protease (MMP9 and cathepsin K) expression essential for their resorptive activity [118]. Similarly, in vivo studies in murine models of basal-like TNBC also demonstrate stromal-specific Hh target gene expression driven by tumor-secreted ligand contributing to tumor growth, invasion, and metastasis [56].

Targeting the Hedgehog Pathway in Triple-Negative Breast Cancer

Hh-targeted therapies currently in use, and those that have been or are presently the subject of clinical investigation, consist of inhibitors directed against the most “druggable” pathway target, SMO (GDC-0449, BMS-833923, LDE-225, PF-04449913, LY2940680, LEQ506, and IPI-926). Although clinical benefit from SMO inhibitors has been established in basal cell carcinoma (BCC) [119, 120] and medulloblastoma [121], their use in other solid tumors including colorectal, pancreatic, or lung cancer has been disappointing [122–124]. Likewise,

Table 2. Mechanisms of deregulated Hh signaling in solid tumors.

| Hh-dependent tumors                  | Mechanisms of deregulated Hh signaling in solid tumors. |
|--------------------------------------|--------------------------------------------------------|
| BCC                                  | Loss of function PTCH mutation (90% of sporadic BCCs) or activating SMO mutation (10% sporadic BCC) |
| Medulloblastoma                       | Loss of function PTCH mutation (10-20% of sporadic medulloblastoma), less commonly activating SMO mutations or GLI amplification |
| Non-Hh-dependent tumors (Hh signaling is nonetheless implicated in tumor cell proliferation, EMT, invasion, migration and drug resistance) | Non-Hh-dependent tumors (Hh signaling is nonetheless implicated in tumor cell proliferation, EMT, invasion, migration and drug resistance) |
| Non-small-cell lung cancer            | Autocrine SMO-dependent signaling: Loss of HHIP or increased HH ligand expression via SOX2-mediated regulation of hedgehog acetyltransferase HHAT expression1) |
| Gastric cancer                       | Ligand (SMO)-independent signaling: Direct GLI2 activation by FGFR1 through MAPK signaling (squamous cell lung cancer) |
| Colorectal cancer                    | Likely non-canonical SMO-dependent signaling (cytoskeletal rearrangement in lung cancer cells) |
| Pancreatic cancer                    | Paracrine stromal signaling (lung fibroblasts) |
| Prostate cancer                      | Ligand (SMO)-independent signaling: Direct GLI1 activation by MAPK signaling |
| Oncogenic K-RAS induces GLI1 activity via MAPK signaling. TGF-β/SMAD signaling directly activates GLI2 |
| Paracrine stromal signaling (in stroma surrounding pseudopyloric metaplastic lesions, and fibroblasts in diffuse-type gastric cancer) |
| Autocrine SMO-dependent signaling    | Ligand (SMO)-independent signaling: Direct GLI1 activation by MAPK, PI3K, and Wntβ-catenin signaling. Loss of p53 and PTEN also shown to increase GLI1 activity |
| Paracrine stromal signaling (in colorectal adenoma and invasive carcinoma) |
| Oncogenic K-RAS induces GLI1 activity via MAPK signaling. TGF-β/SMAD signaling directly activates GLI2 |
| Paracrine stromal signaling (linked to desmoplasia) |

1Hedgehog acetyltransferase catalyzes the rate-limiting step in Hh ligand production. Increased expression of HHAT mediated by SOX2 leads to increased Hh ligand production and ligand-dependent autocrine signaling in squamous cell lung cancer. FGFR1: Fibroblast growth factor receptor 1.
Table 3. Clinical trials with SMO inhibitors allowing enrollment (ongoing studies) or with enrolled (closed studies) breast cancer patients.

| Hedgehog antagonists | Trial | Patient population | Combination/ Comparator arm | Trial Description |
|----------------------|-------|--------------------|-------------------------------|------------------|
| **SMO antagonists**  |       |                    |                               |                  |
| GDC-0449 (Vismodegib) | NCT01071564 Phase I (terminated) | Locally advanced unresectable or metastatic HER-2 negative breast cancer Planned expansion phase limited to TNBC | In combination with Notch inhibitor R04929097 | Primary outcome: Safety Secondary outcomes: PK and PD data Tumor response (RECIST) Hh and BCSC marker expression |
| LDE-225 (Erismodegib/Sonidegib) | NCT01576666 Phase Ib | Metastatic solid tumors including breast cancer (n = 3) | In combination with Pan-PI3K inhibitor buparlisib (BKM120) | Primary outcome: Safety Secondary outcomes: ORR, EPR PK data |
| | NCT02027376 Phase Ib | Advanced and metastatic triple-negative breast cancer (≤3 prior chemotherapy regimens for advanced/metastatic disease) | In combination with docetaxel (every 3 weeks) | Primary outcome: Safety Secondary outcomes: ORR TTP PK data |
| | NCT01757327 Phase II (withdrawn) | Stage II and III triple-negative breast cancer after neoadjuvant/ adjuvant chemotherapy and surgery | Placebo | Primary outcome: Proportion of patients who are bone marrow disseminated tumor cell (DTC)-negative after therapy Secondary outcomes: DFS, OS PTCH1 expression |
| | NCT00880308 Phase I [148] | Advanced or metastatic solid tumors including breast cancer (n = 3) | | Primary outcome: Safety Secondary outcomes: Tumor response (RECIST) Best response (not reported in breast cancer patients enrolled in the study) PK and PD data |
| LY2940680 (Taladegib) | NCT01226485 NCT01919398 Phase I | Advanced solid tumors | | Primary outcome: Safety Secondary outcomes: Number/proportion of patients with tumor response PK data |
| TAK-441 | NCT01204073 Phase I [149] | Advanced solid tumors including breast cancer (n = 1) | | Primary outcome: Safety Secondary outcomes: Tumor response (PD as best response in breast cancer patient) |
| LEQ506 | NCT01106508 Phase I | Advanced or metastastic solid tumors, medulloblastoma, BCC | | Primary outcome: Safety Secondary outcomes: Tumor response PK and PD data |

BCC, Basal cell carcinoma; PK, pharmacokinetic; PG, pharmacogenetic; PD, pharmacodynamic; ORR, overall response rate; EPR, early progression rate; TTP, Time to progression; DFS, Disease-free survival; OS, Overall survival.
Hedgehog Pathway in TNBC

J. G. Habib & J. A. O'Shaughnessy

Itraconazole, a potent SMO inhibitor [125], has also yielded modest clinical benefit when used as single agent in metastatic castrate-resistant prostate cancer [126].

Failure of SMO inhibitors in these malignancies can be at least partly explained in that aberrant Hh signaling in these cancers, unlike medulloblastoma or BCC, is not driven by mutational mechanisms effectively targeted by SMO inhibition. Instead, deregulation of Hh signaling in these malignancies, not unlike breast cancer, is likely due to multiple coexisting mechanisms of pathway activation comprising SMO-dependent autocrine and/or paracrine signaling and SMO-independent signaling through direct regulation of GLI expression or activity (Table 2). Likewise, established and potential mechanisms of Hh pathway activation downstream of SMO, such as loss of tumor suppressor genes, Teashirt zinc finger homeobox 2 (TSHZ2), Liver kinase B1 (LKB1), or Singleminded-2s (SIM2s) [127–129], provide reason to speculate that these drugs may have limited application in TNBC.

Few SMO inhibitor trials on solid tumors have allowed enrollment of breast cancer patients and only three studies (NCT01071564, NCT01757327, and NCT02027376) investigated the use of SMO inhibitors, alone or in combination, exclusively in breast cancer. Pending formal presentation of all study results, preliminary findings suggest limited therapeutic efficacy, and with early closure of two of the breast cancer trials, it is unlikely that we will gain further insight into the clinical value of SMO inhibitors in TNBC (Table 3). In the absence of clinical data, collective findings of preclinical studies are supportive of resistance to SMO antagonists in TNBC and suggest that effective Hh pathway inhibition will necessitate the use of a GLI-targeted approach [42, 43, 54, 55, 90].

Indirect GLI inhibitors

Drugs in this category target GLI proteins indirectly by interfering with mechanisms affecting their transcriptional activity, including post-translational modifications leading to GLI activation/degradation, and epigenetic regulation. For instance, forskolin and pyrvinium enhance PAK and CK1α-mediated GLI1/2 degradation, respectively, [136, 137] whereas staurosporinone and physalins B/F are thought to inhibit PKC-δ/MAPK-mediated GLI activation [138]. Similarly, selective HDAC1/2 inhibitors were shown to antagonize GLI1 and GLI2 activity by counteracting their transcriptional activation induced by deacetylation [60]. Epigenetic silencing of GLI1 and GLI2 proteins by JQ1 and I-BET151 has also been described. Both drugs exert their activity by interfering with bromo and extra-C-terminal (BET) bromodomain protein 4 activity, a key activator of GLI transcription [139, 140].

Of all GLI inhibitors, only GANT58 and GANT61 have been evaluated in TNBC cells with more compelling data on the activity of the latter drug [42, 55, 90, 141]. Despite being the most promising GLI inhibitor to date, it is uncertain whether GANT61 will be suitable for drug development given the lack of information on its pharmacokinetic profile. An important consideration to take into account for the development and selection of direct GLI inhibitors in TNBC is the existence of post-translational processing mechanisms leading to truncated GLI isoforms which may potentially alter the binding affinity or the activity of any specific candidate drug [105].

Indirect GLI inhibitors have emerged as attractive Hh targets mostly due to their favorable characteristics for druggability compared to GLI transcription factors per se, however, their Hh inhibitory activity has not been investigated in TNBC. Taking into account the existence of several distinct oncogenic signals leading to GLI activation in TNBC and the uncertainty that extrinsic GLI activation is subject to similar regulatory mechanisms as endogenous GLI, the efficacy of indirect inhibitors remains unclear.

Furthermore, the functional redundancy of GLI proteins and the implication of both GLI1 and GLI2 in the pathogenesis of TNBC may limit the application of any direct or indirect inhibitor exhibiting preferential activity against one or the other but not both GLI proteins. Therefore, demonstration of potent GLI1/GLI2 inhibitory activity at cytotoxic concentrations will be an important criterion when selecting drugs for clinical development in TNBC.
Conclusion and Perspectives

In this review, we have discussed the current evidence and recent studies highlighting the role of the Hh pathway in the pathogenesis of TNBC and explored mechanisms of deregulated Hh signaling in this breast cancer subtype. The key contribution of extrinsic oncogenic signals, mediated by TGF-β, RAS/MAPK signaling, OPN, NF-kB, FOXCl, and HIF-1α, in driving Hh pathway activation downstream of SMO in TNBC was also reviewed.

Although we have limited information on the use of SMO inhibitors in breast cancer in the clinical setting, the preclinical data we presented suggest resistance to SMO inhibitors in TNBC and instead provide the rationale for a GLI-targeted approach.

The contribution of GLI activation in circumventing SMO inhibition in BCC or medulloblastoma and the recognition of the role of direct mechanisms of GLI activation downstream of SMO in drug resistance, tumor growth, and progression in other solid tumors have provided impetus for identifying potent GLI inhibitors. So far, several direct and indirect inhibitors of GLI have been discovered; yet, their suitability for clinical use is still uncertain. Based on currently available data, the use of direct inhibitors with GLI1/GLI2 activity such as GANT61 may represent the most effective approach at targeting Hh signaling in TNBC. Determining whether epigenetic and post-translational regulatory mechanisms targeted by indirect GLI inhibitors can be overcome by extrinsic GLI activation will be important to ascertain the potential activity of these drugs in TNBC.

Additional questions warranting further investigation include:

Which TNBC patients might benefit from Hh-targeted interventions?

Hh pathway deregulation may not necessarily play a pathogenic role in all subtypes of TNBC; hence, Hh inhibition may prove to be of limited value among unselected patients. A recent analysis of a dataset of over 330 tumor samples yielded evidence for preferential GLI1 expression in claudin-low relative to other basal tumors and higher sensitivity to GLI inhibition was observed in claudin-low cell lines. Recognizing the heterogeneity of TNBC and limiting future studies to specific molecular subtypes, such as claudin-low subtype, enriched for BCSCs may potentially identify subgroups of TNBC patients who might benefit from Hh-targeted interventions.

In addition, no biomarker predictive of clinical benefit from SMO antagonists in other solid tumors has been identified to date. It is uncertain as to whether or not this endeavor has been unsuccessful due to ineffective Hh signaling inhibition in these cancers, which, not unlike TNBC, are characterized by downstream pathway activation not targeted by SMO antagonists. As the development of GLI inhibitors moves forward, integration of putative predictive biomarkers in clinical studies evaluating the use of these drugs in TNBC will be of paramount importance.

When should Hh-targeted intervention be timed during treatment?

Data presented in this review implicate chemotherapy-induced Hh signaling activation in BCSC expansion and tumor regrowth in TNBC. It is unclear whether chemotherapy "selects" for the survival of BCSCs subpopulations in TNBC or promotes stromal metabolic stress leading to the acquisition of stem-like phenotype by differentiated tumor cells. Nevertheless, based on the current evidence, targeting Hh signaling after completion of chemotherapy seems intuitive and the application of Hh-targeted strategies in the future may conceivably be limited to TNBC patients who have failed to achieve clinical or pathologic complete response to neoadjuvant chemotherapy. Studies evaluating mechanisms of deregulated Hh signaling following chemotherapy in TNBC are scarce. In the absence of these data, one cannot assume that these mechanisms are identical to those driving Hh signaling in chemotherapynaïve TNBC. Further insight into the signaling machinery contributing to deregulated Hh signaling following chemotherapy in TNBC, both in preclinical models of residual tumor and clinical tumor samples after neoadjuvant chemotherapy, is therefore necessary.

Should drug combination strategies be used when planning Hh-targeted therapeutic interventions in TNBC?

Hh, TGF-β, PI3K/AKT, RAS/MAPK signaling possess overlapping functionality in TNBC; potential crosstalk between Hh and these signaling pathways could potentially circumvent pharmacological Hh inhibition. Thus, uncovering mechanisms of crosstalk between Hh signaling and other key tumorigenic pathways in TNBC can provide the basis for the development of effective combination therapies. A synergistic therapeutic effect has been reported in non-mammary solid tumors when combined targeting of GLI and PI3K/AKT or GLI and EGFR signaling was used [142–145]. Exploring potential synergy between Hh and EGFR signaling specifically may be of particular relevance in TNBC, as the rationale for a GLI- targeted approach.
for EGFR inhibitor failure in this breast cancer subtype remains elusive.

Is there a role for stromal Hh signaling inhibition in TNBC?

Despite the potential resistance of TNBC cells to SMO modulation, stromal paracrine signaling is, on the other hand, SMO-dependent and consequently may be amenable to modulation by SMO antagonists. Classically, Hh signaling in the stromal microenvironment was thought to foster tumor growth and invasion, and corroborative preclinical data have revealed potential benefit for the use of SMO modulation and stromal inhibition in TNBC [117, 118]. However, recent reports have challenged the hypothesis of pro-tumorigenic stromal Hh signaling demonstrating, contrariwise, that stromal signaling may exert a tumor suppressive and antiangiogenic role in pancreatic cancer [146, 147]. Based on these findings, Hh inhibition and stromal depletion might seemingly be a counterintuitive approach for preventing tumor progression. Extrapolation of similar conclusions in TNBC is difficult given the differences between oncogenic mechanisms driving tumor and stromal Hh signaling in pancreatic cancer and TNBC. Accordingly, further investigation is needed to better understand the mechanisms of stromal Hh signaling in TNBC and the potential effect of stromal modulation on tumor growth both in early and late-stage disease.

Acknowledgments

The authors thank Alex Tong, PhD, for assistance in researching and writing the manuscript, Maren K. Levin, MS, for assistance in formatting the manuscript, and Sarah Armstrong for managing the project.

Conflict of Interest

The authors declare they have no competing interests.

References

1. Elsawaf, Z., H.-P. Sinn, J. Rom, J. L. Bermejo, A. Schneeweiss, and S. Aulmann. 2013. Biological subtypes of triple-negative breast cancer are associated with distinct morphological changes and clinical behaviour. Breast 22:986–992.
2. Lehmann, B. D., J. A. Bauer, X. Chen, M. E. Sanders, A. B. Chakravarthy, Y. Shyr, et al. 2011. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121:2750–2767.
3. Shah, S. P., A. Roth, R. Goya, A. Oloumi, G. Ha, Y. Zhao, et al. 2012. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486:395–399.
4. Weisman, P. S., C. K. Y. Ng, E. Brogi, R. E. Eisenberg, H. H. Won, S. Piscuoglio, et al. 2016. Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology. Mod. Pathol. 29:476–488.
5. Kim, J. E., H. J. Ahn, J.-H. Ahn, D. H. Yoon, S.-B. Kim, K. H. Jung, et al. 2012. Impact of triple-negative breast cancer phenotype on prognosis in patients with stage I breast cancer. J. Breast Cancer 15:197–202.
6. Metzger-Filho, O., Z. Sun, G. Viale, K. N. Price, D. Crivellari, R. D. Snyder, et al. 2013. Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX. J. Clin. Oncol. 31:3083–3090.
7. Dent, R., M. Trudeau, K. I. Pritchard, W. M. Hanna, H. K. Kahn, C. A. Sawka, et al. 2007. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 13(15 Pt 1):4429–4434.
8. Lehmann, B. D., J. A. Bauer, J. M. Schafer, C. S. Pendleton, L. Tang, K. C. Johnson, et al. 2014. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res. 16:406.
9. Masuda, H., K. A. Baggerly, Y. Wang, Y. Zhang, A. M. Gonzalez-Angulo, F. Meric-Bernstam, et al. 2013. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin. Cancer Res. 19:5533–5540.
10. Crown, J., J. O’Shaughnessy, and G. Gullo. 2012. Emerging targeted therapies in triple-negative breast cancer. Ann. Oncol. 23(Suppl 6):vi56–vi65.
11. Al-Hajj, M., M. S. Wicha, A. Benito-Hernandez, S. J. Morrison, and M. F. Clarke. 2003. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100:3983–3988.
12. Ginestier, C., M. H. Hur, E. Charafe-Jauffret, F. Monville, J. Dutcher, M. Brown, et al. 2007. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1:555–567.
13. Ponti, D., A. Costa, N. Zaffaroni, G. Pratesi, G. Petrangolini, D. Coradini, et al. 2005. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 65:5506–5511.
14. Dontu, G., and M. S. Wicha. 2005. Survival of mammary stem cells in suspension culture: implications for stem cell biology and neoplasia. J. Mammary Gland Biol. Neoplasia 10:75–86.

15. Fillmore, C. M., and C. Kuperwasser. 2008. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 10:R25.

16. Tanei, T., K. Morimoto, K. Shimazu, S. J. Kim, Y. Tanji, T. Taguchi, et al. 2009. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin. Cancer Res. 15:4234–4241.

17. Sheridan, C., H. Kishimoto, R. K. Fuchs, S. Mehrotra, P. Bhat-Nakshatri, C. H. Turner, et al. 2006. CD44+/CD24− breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res. 8:R39.

18. Croker, A. K., D. Goodale, J. Chu, C. Postenka, B. D. Hedley, D. A. Hess, et al. 2009. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J. Cell Mol. Med. 13:2236–2252.

19. Liu, R., X. Wang, G. Y. Chen, P. Delarba, A. Gurney, T. Hoey, et al. 2007. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N. Engl. J. Med. 356:217–226.

20. Charafe-Jauffret, E., C. Ginestier, F. Iovino, C. Tarpin, M. Diebel, B. Esterni, et al. 2010. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin. Cancer Res. 16:45–55.

21. Leth-Larsen, R., M. G. Terp, A. G. Christensen, D. Elias, T. Kühlwein, O. N. Jensen, et al. 2012. Functional heterogeneity within the CD44 high human breast cancer stem cell-like compartment reveals a gene signature predictive of distant metastasis. Mol. Med. 18:1109–1121.

22. Prat, A., J. S. Parker, O. Karginova, C. Fan, C. Livasy, J. I. Herschkowitz, et al. 2010. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 12:R68.

23. Zhang, Y., K. A. Toy, and C. G. Kleer. 2012. Metaplastic breast carcinomas are enriched in markers of tumor-initiating cells and epithelial to mesenchymal transition. Mod. Pathol. 25:178–184.

24. Honeth, G., P.-O. Bendahl, M. Ringnér, L. H. Saal, S. K. Gruvberger-Saal, K. Lövgren, et al. 2008. The CD44+/CD24− phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 10:R53.

25. Nalwoga, H., J. B. Arnes, H. Wabinga, and L. A. Akslen. 2010. Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer. Br. J. Cancer 102:369–375.

26. Taube, J. H., J. I. Herschkowitz, K. Komurov, A. Y. Zhou, S. Gupta, J. Yang, et al. 2010. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc. Natl Acad. Sci. USA 107:15449–15454.

27. Idowu, M. O., M. Kmiecik, C. Dumur, R. S. Burton, M. M. Grimes, C. N. Powers, et al. 2012. CD44(+)/CD24(−/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum. Pathol. 43:364–373.

28. Morel, A.-P., M. Lièvre, C. Thomas, G. Hinkal, S. Ansieau, and A. Puisieux. 2008. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS ONE 3:e2888.

29. Himohara, K., S. Kobayashi, H. Kanauchi, S. Shimizu, K. Nishioka, E. Tsuji, et al. 2012. ErbB receptor tyrosine kinase/NF-κB signaling controls mammosphere formation in human breast cancer. Proc. Natl Acad. Sci. USA 109:6584–6589.

30. Liu, S., G. Dontu, I. D. Mantle, S. Patel, N. Ahn, K. W. Jackson, et al. 2006. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 66:6063–6071.

31. D’Angelo, R. C., M. Ouzounova, A. Davis, D. Choi, S. M. Tchuenkam, G. Kim, et al. 2015. Notch reporter activity in breast cancer cell lines identifies a subset of cells with stem cell activity. Mol. Cancer Ther. 14:779–787.

32. Scheel, C., E. N. Eaton, S. H.-J. Li, C. L. Chaffer, F. Reinhardt, K.-J. Kah, et al. 2011. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 145:926–940.

33. Riddle, R. D., R. L. Johnson, E. Laufer, and C. Tabin. 1993. Sonic hedgehog mediates the polarizing activity of the ZPA. Cell 75:1401–1416.

34. Dessaud, E., A. P. McMahon, and J. Briscoe. 2008. Pattern formation in the vertebrate neural tube: a sonic hedgehog morphogen-regulated transcriptional network. Development 135:2489–2503.

35. Machold, R., S. Hayashi, M. Rutlin, M. D. Muzumdar, S. Nery, J. G. Corbin, et al. 2003. Sonic hedgehog is required for progenitor cell maintenance in telencephalic stem cell niches. Neuron 39:937–950.

36. Bhadrwaj, G., B. Murdoch, D. Wu, D. P. Baker, K. P. Williams, K. Chadwick, et al. 2001. Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation. Nat. Immunol. 2:172–180.

37. Gailani, M. R., M. Ståhle-Bäckdahl, D. J. Leffell, M. Glynn, P. G. Zaphiropoulos, C. Pressman, et al. 1996.
The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat. Genet. 14:78–81.

38. Raffel, C., R. B. Jenkins, L. Frederick, D. Hebrink, B. Alderete, D. W. Fults, et al. 1997. Sporadic medulloblastomas contain PTCH mutations. Cancer Res. 57:842–845.

39. Ramaswamy, B., Y. Lu, K. Teng, G. Nuovo, X. Li, C. L. Shapiro, et al. 2012. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway. Cancer Res. 72:5048–5059.

40. Sun, Y., Y. Wang, C. Fan, P. Gao, X. Wang, G. Wei, et al. 2014. Estrogen promotes stemness and invasiveness of ER-positive breast cancer cells through GLI1 activation. Mol. Cancer. 13:137.

41. Sims-Mourtada, J., L. M. Opdenaker, J. Davis, K. M. Shapiro, et al. 2014. Hedgehog signaling is a novel therapeutic target in tamoxifen resistance breast cancer. Mol. Med. 5:488–508.

42. Thomas, Z. I., W. Gibson, J. Z. Sexton, K. M. Aird, S. M. Ingram, A. Aldrich, et al. 2011. Targeting GLI1 expression in human inflammatory breast cancer cells enhances apoptosis and attenuates migration. Br. J. Cancer 104:1575–1586.

43. Sims-Mourtada, J., L. M. Opdenaker, J. Davis, K. M. Arnold, and D. Flynn. 2014. Taxane-induced hedgehog signaling is linked to expansion of breast cancer stem-like populations after chemotherapy. Mol. Carcinog. 54:1480–1493.

44. Harris, L. G., L. K. Pannell, S. Singh, R. S. Samant, and L. A. Shevde. 2012. Increased vascularity and spontaneous metastasis of breast cancer by hedgehog signaling mediated upregulation of cyr61. Oncogene 31:3370–3380.

45. Colavito, S. A., M. R. Zou, Q. Yan, D. X. Nguyen, and D. F. Stern. 2014. Significance of glioma-associated oncogene homolog 1 (GLI1) expression in claudin-low breast cancer and crosstalk with the nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) pathway. Breast Cancer Res. 16:444.

46. Kwon, Y.-J., D. R. Hurst, A. D. Steg, K. Yuan, K. S. Vaidya, D. R. Welch, et al. 2011. GLI1 enhances migration and invasion via up-regulation of MMP-11 and promotes metastasis in ERα negative breast cancer cell lines. Clin. Exp. Metastasis 28:437–449.

47. Sasai, N., and J. Briscoe. 2012. Primary cilia and graded Sonic Hedgehog signaling. Wiley Interdiscip. Rev. Dev. Biol. 1:753–772.

48. Alexandre, C., A. Jacinto, and P. W. Ingham. 1996. Transcriptional activation of hedgehog target genes in Drosophila is mediated directly by the cubitus interruptus protein, a member of the GLI family of zinc finger DNA-binding proteins. Genes Dev. 10:2003–2013.

49. Ruppert, J. M., K. W. Kinzler, A. J. Wong, S. H. Bigner, F. T. Kao, M. L. Law, et al. 1988. The GLI-Kruppel family of human genes. Mol. Cell. Biol. 8:3104–3113.

50. Sasaki, H., Y. Nishizaki, C. Hui, M. Nakafuku, and H. Kondoh. 1999. Regulation of GLI2 and GLI3 activities by an amino-terminal repression domain: implication of GLI2 and GLI3 as primary mediators of Shh signaling. Development 126:3915–3924.

51. Bai, C. B., W. Auerbach, J. S. Lee, D. Stephen, and A. L. Joyner. 2002. GLI2, but not GLI1, is required for initial Shh signaling and ectopic activation of the Shh pathway. Development 129:4753–4761.

52. Persson, M., D. Stamatakis, P. te Welscher, E. Andersson, J. Böse, U. Rüther, et al. 2002. Dorsal-ventral patterning of the spinal cord requires GLI3 transcriptional repressor activity. Genes Dev. 16:2865–2878.

53. Hatsell, S. J., and P. Cowin. 2006. GLI3-mediated repression of Hedgehog targets is required for normal mammary development. Development 133:3661–3670.

54. Johnson, R. W., M. P. Nguyen, S. S. Padalecki, B. G. Grubbs, A. R. Merkel, B. O. Oyajobi, et al. 2011. TGF-beta promotion of GLI2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling. Cancer Res. 71:822–831.

55. Das, S., R. S. Samant, and L. A. Shevde. 2013. Nonclassical activation of Hedgehog signaling enhances multidrug resistance and makes cancer cells refractory to Smoothened-targeting Hedgehog inhibition. J. Biol. Chem. 288:11824–11833.

56. O’Toole, S. A., D. A. Machalek, R. F. Shearer, E. K. A. Millar, R. Nair, P. Schofield, et al. 2011. Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer. Cancer Res. 71:4002–4014.

57. Stecca, B., I. Ruiz, and A. Altaba. 2010. Context-dependent regulation of the GLI code in cancer by HEDGEHOG and non-HEDGEHOG signals. J. Mol. Cell Biol. 2:84–95.

58. Tempé, D., M. Casas, S. Karaz, M.-F. Blanchet-Tournier, and J.-P. Concorde. 2006. Multisite protein kinase A and glycogen synthase kinase 3beta phosphorylation leads to GLI3 ubiquitination by SCFBetaTrCP. Mol. Cell. Biol. 26:4316–4326.

59. Varjosalo, M., M. Björklund, F. Cheng, H. Syvänen, T. Kivioja, S. Kilpinen, et al. 2008. Application of active and kinase-deficient kinome collection for identification of kinases regulating hedgehog signaling. Cell 133:537–548.

60. Canettieri, G., L. Di Marcotullio, A. Greco, S. Coni, L. Antonucci, P. Infante, et al. 2010. Histone deacetylase
and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation. Nat. Cell Biol. 12:132–142.

61. Coni, S., L. Antonucci, D. D’Amico, L. Di Magno, P. Infante, E. De Smaele, et al. 2013. Gli2 acetylation at lysine 757 regulates hedgehog-dependent transcriptional output by preventing its promoter occupancy. PLoS ONE 8:e65718.

62. Stecca, B., C. Mas, V. Clement, M. Zbinden, R. Correa, V. Piguet, et al. 2007. Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/ AKT pathways. Proc. Natl Acad. Sci. USA 104:5895–5900.

63. Seto, M., M. Ohta, Y. Asaoka, T. Ikenoue, M. Tada, K. Miyabayashi, et al. 2009. Regulation of the HEDGEHOG-GLI signaling pathway by the mitogen-activated protein kinase cascade in gastric cancer. Mol. Carcinog. 48:703–712.

64. Ji, Z., F. C. Mei, J. Xie, and X. Cheng. 2007. Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells. J. Biol. Chem. 282:14048–14055.

65. Riobó, N. A., K. Lu, X. Ai, G. M. Haines, and C. P. Emerson. 2006. Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling. Proc. Natl Acad. Sci. USA 103:4505–4510.

66. Duan, Z.-H., H.-C. Wang, D.-M. Zhao, X.-X. Ji, M. Song, X.-J. Yang, et al. 2015. Cooperatively transcriptional and epigenetic regulation of sonic hedgehog overexpression drives malignant potential of breast cancer. Cancer Sci. 106:1084–1091.

67. Dennler, S., J. André, F. Verrecchia, and A. Mauviel. 2009. Cloning of the human GLI2 Promoter: transcriptional activation by transforming growth factor-beta via SMAD3/beta-catenin cooperation. J. Biol. Chem. 284:31523–31531.

68. Brennan, D., X. Chen, L. Cheng, M. Mahoney, and N. A. Riobo. 2012. Noncanonical Hedgehog signaling. Vitam. Horm. 88:55–72.

69. Lauth, M., and R. Toftgård. 2007. Noncanonical activation of GLI transcription factors: implications for targeted anti-cancer therapy. Cell Cycle 6:2458–2463.

70. Singh, S., Z. Wang, D. Liang Fei, K. E. Black, J. A. Goetz, R. Tokhunts, et al. 2011. Hedgehog-producing cancer cells respond to and require autocrine Hedgehog activity. Cancer Res. 71:4454–4463.

71. Liu, Z., J. Xu, J. He, Y. Zheng, H. Li, Y. Lu, et al. 2014. A critical role of autocrine sonic hedgehog signaling in human CD138+ myeloma cell survival and drug resistance. Blood 124:2061–2071.

72. Li, X., Z. Wang, Q. Ma, Q. Xu, H. Liu, W. Duan, et al. 2014. Sonic hedgehog paracrine signaling activates stromal cells to promote perineural invasion in pancreatic cancer. Clin. Cancer 20:4326–4338.

73. Chan, I. S., C. D. Guy, Y. Chen, J. Lu, M. Swiderska-Syn, G. A. Michelotti, et al. 2012. Paracrine Hedgehog signaling drives metabolic changes in hepatocellular carcinoma. Cancer Res. 72:6344–6350.

74. Dierks, C., J. Gribic, K. Zirilk, R. Beigi, N. P. Englund, G.-R. Guo, et al. 2007. Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat. Med. 13:944–951.

75. Reifenberger, J., M. Wolter, R. G. Weber, M. Megahed, T. Ruzicka, P. Lichter, et al. 1998. Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res. 58:1798–1803.

76. Roberts, W. M., E. C. Douglass, S. C. Peiper, P. J. Houghton, and A. T. Look. 1989. Amplification of the gli gene in childhood sarcomas. Cancer Res. 49:5407–5413.

77. Xie, J., R. L. Johnson, X. Zhang, J. W. Bare, F. M. Waldman, P. H. Cogen, et al. 1997. Mutations of the PATCHED gene in several types of sporadic extracutaneous tumors. Cancer Res. 57:2369–2372.

78. Oro, A. E., K. M. Higgins, Z. Hu, J. M. Bonifas, E. H. Epstein, and M. P. Scott. 1997. Basal cell carcinomas in mice overexpressing sonic hedgehog. Science 286:817–821.

79. Jiao, X., L. D. Wood, M. Lindman, S. Jones, P. Buckhaults, K. Polyak, et al. 2012. Somatic mutations in the Notch, NF-KB, PIK3CA, and Hedgehog pathways in human breast cancers. Genes Chromosom. Cancer 51:480–489.

80. Vorechovský, I., K. P. Benediktsson, and R. Toftgård. 1999. The patched/hedgehog/smoothened signalling pathway in human breast cancer: no evidence for H133Y SHH, PTCH and SMO mutations. Eur. J. Cancer 35:711–713.

81. Wicking, C., T. Evans, B. Henk, N. Hayward, L. A. Simms, G. Chenevix-Trench, et al. 1998. No evidence for the H133Y mutation in SONIC HEDGEHOG in a collection of common tumour types. Oncogene 16:1091–1093.

82. Wakabayashi, Y., J.-H. Mao, K. Brown, M. Girardi, and A. Balmain. 2007. Promotion of Hras-induced squamous carcinomas by a polymorphic variant of the Patched gene in FVB mice. Nature 445:761–765.

83. Mille, F., C. Thibert, J. Fombonne, N. Rama, C. Guix, H. Hayashi, et al. 2009. The Patched dependence receptor triggers apoptosis through a DRAL-caspase-9 complex. Nat. Cell Biol. 11:739–746.

84. Chang, H., L. Balenci, N. Okolowsky, W. J. Muller, and P. A. Hamel. 2012. Mammary epithelial-restricted expression of activated c-src rescues the block to mammary gland morphogenesis due to the
deletion of the C-terminus of Patched-1. Dev. Biol. 370:187–197.
85. Okolowsky, N., P. A. Furth, and P. A. Hamel. 2014. Oestrogen receptor-alpha regulates non-canonical Hedgehog-signalling in the mammary gland. Dev. Biol. 391:219–229.
86. Harvey, M. C., A. Fleet, N. Okolowsky, and P. A. Hamel. 2014. Distinct effects of the mesenchymal dysplasia gene variant of murine Patched-1 protein on canonical and non-canonical Hedgehog signaling pathways. J. Biol. Chem. 289:10939–10949.
87. Chinchilla, P., L. Xiao, M. G. Kazanietz, and N. A. Riobo. 2010. Hedgehog proteins activate pro-angiogenic responses in endothelial cells through non-canonical signaling pathways. Cell Cycle 9:570–579.
88. Polizio, A. H., P. Chinchilla, X. Chen, S. Kim, D. R. Manning, and N. A. Riobo. 2011. Heterotrimeric G protein-coupled Hedgehog signaling to activation of Rho small GTPases to promote fibroblast migration. J. Biol. Chem. 286:19589–19596.
89. Razumilava, N., S. A. Gradilone, R. L. Smoot, J. C. Mertens, S. F. Bronk, A. E. Sirica, et al. 2014. Non-canonical Hedgehog signaling contributes to metastasis in cholangiocarcinoma. J. Hepatol. 60:599–605.
90. Han, B., Y. Qu, Y. Jin, Y. Yu, N. Deng, K. Wawrowsky, et al. 2015. FOXC1 activates smoothened-independent Hedgehog signaling in basal-like breast cancer. Cell Rep. 13:1046–1058.
91. Ke, Z., S. Caiping, Z. Qing, and W. Xiaojing. 2015. Sonic hedgehog-Gli1 signals promote epithelial-mesenchymal transition in ovarian cancer by mediating PI3K/AKT pathway. Med. Oncol. 32:368.
92. Yamamichi, F., K. Shigemura, H. M. Behnsawy, F. Y. Meligy, W.-C. Huang, X. Li, et al. 2014. Sonic hedgehog and androgen signaling in tumor and stromal compartments drives epithelial-mesenchymal transition in prostate cancer. Scand. J. Urol. 48:523–532.
93. Lei, J., J. Ma, Q. Ma, X. Li, H. Liu, Q. Xu, et al. 2013. Hedgehog signaling regulates hypoxia induced epithelial to mesenchymal transition and invasion in pancreatic cancer cells via a ligand-independent manner. Mol. Cancer. 12:66.
94. Yue, D., H. Li, J. Che, Y. Zhang, H.-H. K. Tseng, J. Q. Jin, et al. 2014. Hedgehog/Gli1 promotes epithelial-mesenchymal transition in lung squamous cell carcinomas. J. Exp. Clin. Cancer Res. 33:34.
95. Lei, J., L. Fan, G. Wei, X. Chen, W. Duan, Q. Xu, et al. 2015. Gli-1 is crucial for hypoxia-induced epithelial-mesenchymal transition and invasion of breast cancer. Tumour Biol. 36:3119–3126.
96. Mani, S. A., W. Guo, M.-J. Liao, E. N. Eaton, A. Ayyanan, A. Y. Zhou, et al. 2008. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704–715.
97. Hollier, B. G., A. A. Tinnirello, S. J. Werden, K. W. Evans, J. H. Taube, T. R. Sarkar, et al. 2013. FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer. Cancer Res. 73:1981–1992.
98. Yang, C., H. Chen, G. Tan, W. Gao, L. Cheng, X. Jiang, et al. 2013. FOXM1 promotes the epithelial to mesenchymal transition by stimulating the transcription of Slug in human breast cancer. Cancer Lett. 340:104–112.
99. Ikenouchi, J., M. Matsuda, M. Furuse, and S. Tsukita. 2003. Regulation of tight junctions during the epithelium-mesenchyme transition: direct repression of the gene expression of claudins/occludin by Snail. J. Cell Sci. 116(Pt 10):1959–1967.
100. Kokkinos, M. I., R. Wafai, M. K. Wong, D. F. Newgreen, E. W. Thompson, and M. Waltham. 2007. Vimentin and epithelial-mesenchymal transition in human breast cancer–observations in vitro and in vivo. Cells Tissues Organs 185:191–203.
101. Visbal, A. P., H. L. LaMarca, H. Villanueva, M. J. Toneff, Y. Li, J. M. Rosen, et al. 2011. Altered differentiation and paracrine stimulation of mammary epithelial cell proliferation by conditionally activated Smoothened. Dev. Biol. 352:116–127.
102. García-Zaragoza, E., R. Pérez-Tavarez, A. Ballester, V. Lafargue, A. Jiménez-Reinoso, A. Ramirez, et al. 2012. Intraepithelial paracrine Hedgehog signaling induces the expansion of ciliated cells that express diverse progenitor cell markers in the basal epithelium of the mouse mammary gland. Dev. Biol. 372:28–44.
103. Fiaschi, M., B. Rozell, A. Bergström, and R. Tofgård. 2009. Development of mammary tumors by conditional expression of GLI1. Cancer Res. 69:4810–4817.
104. Kameda, C., H. Tanaka, A. Yamasaki, M. Nakamura, K. Koga, N. Sato, et al. 2009. The Hedgehog pathway is a possible therapeutic target for patients with estrogen receptor-negative breast cancer. Anticancer Res. 29:871–879.
105. Cao, X., J. Geradts, M. W. Dewhirst, and H.-W. Lo. 2012. Upregulation of VEGF-A and CD24 gene expression by the tGLI1 transcription factor contributes to the aggressive behavior of breast cancer cells. Oncogene 31:104–115.
106. Sterling, J. A., B. O. Oyajobi, B. Grubbs, S. S. Padalecki, S. A. Munoz, A. Gupta, et al. 2006. The hedgehog signaling molecule Gli2 induces parathyroid hormone-related peptide expression and osteolysis in metastatic human breast cancer cells. Cancer Res. 66:7548–7553.
107. Tao, Y., J. Mao, Q. Zhang, and L. Li. 2011. Overexpression of Hedgehog signaling molecules and
its involvement in triple-negative breast cancer. Oncol. Lett. 2:995–1001.
108. Pratap, I., J. J. Wixted, T. Gaur, S. K. Zaidi, J. Dobson, K. D. Gokul, et al. 2008. Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells. Cancer Res. 68:7795–7802.
109. Wang, J., P. S. Ray, M.-S. Sim, X. Z. Zhou, K. P. Lu, A. V. Lee, et al. 2012. FOXC1 regulates the functions of human basal-like breast cancer cells by activating NF-κB signaling. Oncogene 31:4798–4802.
110. Yu, Y., C.-H. Xiao, L.-D. Tan, Q.-S. Wang, X.-Q. Li, and Y.-M. Feng. 2014. Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-β signalling. Br. J. Cancer 110:724–732.
111. Angelucci, C., G. Maulucci, G. Lama, G. Proietti, A. Colabianchi, M. Papi, et al. 2012. Epithelial-stromal interactions in human breast cancer: effects on adhesion, plasma membrane fluidity and migration speed and directness. PLoS ONE 7:e50804.
112. Tacchini, L., C. De Ponti, E. Matteucci, R. Follis, and M. A. Desiderio. 2004. Hepatocyte growth factor-activated NF-kappaB regulates HIF-1 activity and ODC expression, implicated in survival, differently in different carcinoma cell lines. Carcinogenesis 25:2089–2100.
113. Das, S., L. G. Harris, B. J. Metge, S. Liu, A. I. Riker, R. S. Samant, et al. 2009. The hedgehog pathway transcription factor GLI1 promotes malignant behavior of cancer cells by up-regulating osteopontin. J. Biol. Chem. 284:22888–22897.
114. Peiris-Pagès, M., F. Sotgia, and M. P. Lisanti. 2015. Chemotherapy induces the cancer-associated fibroblast phenotype, activating paracrine Hedgehog-GLI signalling in breast cancer cells. Oncotarget 6:10728–10745.
115. Arnold, K. M. 2015. Activation of inflammatory responses correlates with hedgehog activation and precede expansion of cancer stem-like cells in an animal model of residual triple negative breast cancer following neoadjuvant chemotherapy. Cancer Stud. Mol. Med. 22:80–86.
116. Mukherjee, S., N. Frolova, A. Sadlonova, Z. Novak, A. Steg, G. P. Page, et al. 2006. Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer. Cancer Biol. Ther. 5:674–683.
117. Heller, E., M. A. Hurchla, J. Xiang, X. Su, S. Chen, J. Schneider, et al. 2012. Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironment. Cancer Res. 72:897–907.
118. Das, S., R. S. Samant, and L. A. Shevde. 2011. Hedgehog signaling induced by breast cancer cells promotes osteoclastogenesis and osteolysis. J. Biol. Chem. 286:9612–9622.
119. Sekulic, A., M. R. Migden, A. E. Oro, L. Dirix, K. D. Lewis, J. D. Hainsworth, et al. 2012. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N. Engl. J. Med. 366:2171–2179.
120. Von Hoff, D. D., P. M. LoRusso, C. M. Rudin, J. C. Reddy, R. L. Yauch, R. Tribes, et al. 2009. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N. Engl. J. Med. 361:1164–1172.
121. Robinson, G. W., B. A. Orr, G. Wu, S. Gururangan, T. Lin, I. Qaddoumi, et al. 2015. Vismodegib exerts targeted efficacy against recurrent sonic hedgehog-subgroup medulloblastoma: results from phase II pediatric brain tumor consortium studies PBTC-025B and PBTC-032. J. Clin. Oncol. 33:2646–2654.
122. Kim, E. J., V. Sahai, E. V. Abel, K. A. Griffith, J. K. Greenroom, N. Takebe, et al. 2014. Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma. Clin. Cancer 20:5937–5945.
123. Berlin, J., J. C. Bendell, L. L. Hart, I. Firdaus, I. Gore, R. C. Hermann, et al. 2013. A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. Clin. Cancer 19:258–267.
124. Belani, C. P., S. E. Dahlberg, C. M. Rudin, M. Fleisher, H. X. Chen, N. Takebe, et al. 2016. Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1508). Cancer 122:2371–2378.
125. Kim, J., J. Y. Tang, R. Gong, J. Kim, J. J. Lee, K. V. Clemons, et al. 2010. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell 17:388–399.
126. Antonarakis, E. S., E. I. Heath, D. C. Smith, D. Rathkopf, A. L. Blackford, D. C. Danila, et al. 2013. Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. Oncologist 18:163–173.
127. Riku, M., S. Inaguma, H. Ito, T. Tsunoda, H. Ikeda, and K. Kasai. 2015. Down-regulation of the zinc-finger homeobox protein TSHZ2 releases GLI1 from the nuclear repressor complex to restore its transcriptional activity during mammary tumorigenesis. Oncotarget 7:5690–5701.
Hedgehog Pathway in TNBC

128. Zhuang, Z., K. Wang, X. Cheng, X. Qu, B. Jiang, Z. Li, et al. 2013. LKB1 inhibits breast cancer partially through repressing the Hedgehog signaling pathway. PLoS ONE 8:e67431.

129. Scribner, K. C., F. Behbod, and W. W. Porter. 2013. Regulation of DCIS to invasive breast cancer progression by Single minded-2s (SIM2s). Oncogene 32:2631–2639.

130. Lauth, M., A. Bergström, T. Shimokawa, and R. Toftgård. 2007. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc. Natl Acad. Sci. USA 104:8455–8460.

131. Agyeman, A., B. K. Jha, T. Mazumdar, and J. A. Houghton. 2014. Mode and specificity of binding of the small molecule GANT61 to GLI determines inhibition of GLI-DNA binding. Oncotarget 5:4492–4503.

132. Infante, P., M. Mori, R. Alfonsi, F. Ghirga, F. Aiello, S. Toscano, et al. 2015. Gli1/DNA interaction is a druggable target for Hedgehog-dependent tumors. EMBO J. 34:200–217.

133. Hyman, J. M., A. J. Firestone, V. M. Heine, Y. Zhao, C. A. Ocasio, K. Han, et al. 2009. Small-molecule inhibitors reveal multiple strategies for Hedgehog pathway blockade. Proc. Natl Acad. Sci. USA 106:14132–14137.

134. Kim, J., J. J. Lee, J. Kim, D. Gardner, and P. A. Beachy. 2010. Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc. Natl Acad. Sci. USA 107:13432–13437.

135. Beauchamp, E. M., L. Ringer, G. Bulut, K. P. Sajwan, M. D. Hall, Y.-C. Wu, X. S. Liu, et al. 2011. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. J. Clin. Invest. 121:148–160.

136. Makinodan, E., and A. G. Marneros. 2012. Protein kinase A activation inhibits oncosgenic Sonic hedgehog signalling and suppresses basal cell carcinoma of the skin. Exp. Dermatol. 21:847–852.

137. Li, B., D. L. Fei, C. A. Flaveny, N. Dahmane, V. Baubet, Z. Wang, et al. 2014. Pyrvinium attenuates Hedgehog signaling downstream of smoothened. Cancer Res. 74:4811–4821.

138. Hosoya, T., M. A. Arai, T. Koyano, T. Kowithayakorn, and M. Ishibashi. 2008. Naturally occurring small-molecule inhibitors of hedgehog/GLI-mediated transcription. ChemBioChem 9:1082–1092.

139. Long, J., B. Li, J. Rodriguez-Blanco, C. Pastori, C.-H. Volmar, C. Wahlestedt, et al. 2014. The BET bromodomain inhibitor I-BET151 acts downstream of smoothened protein to abrogate the growth of hedgehog protein-driven cancers. J. Biol. Chem. 289:35494–35502.

140. Tang, Y., S. Gholamin, S. Schubert, M. I. Willardson, A. Lee, P. Bandopadhyay, et al. 2014. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nat. Med. 20:732–740.

141. Benvenuto, M., L. Masuelli, E. De Smaele, M. Fantini, R. Mattera, D. Cucchi, et al. 2016. In vitro and in vivo inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors. Oncotarget 7:9250–9270.

142. Gruber Filbin, M., S. K. Dabral, M. F. Pazya-Murphy, S. Ramkissoon, A. L. Kung, E. Pak, et al. 2013. Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities. Nat. Med. 19:1518–1523.

143. Graab, U., H. Hahn, and S. Fulda. 2015. Identification of a novel synthetic lethality of combined inhibition of hedgehog and PI3K signaling in rhabdomyosarcoma. Oncotarget 6:8722–8735.

144. Eberl, M., S. Klingler, D. Mangelberger, A. Loipetzberger, H. Damhofer, K. Zoidl, et al. 2012. Hedgehog-EGFR cooperation response genes determine the oncogenic phenotype of basal cell carcinoma and tumour-initiating pancreatic cancer cells. EMBO Mol. Med. 4:218–233.

145. Cai, X., K. Yu, L. Zhang, Y. Li, Q. Li, Z. Yang, et al. 2015. Synergistic inhibition of colon carcinoma cell growth by Hedgehog-Gli1 inhibitor arsenic trioxide and phosphoinositide 3-kinase inhibitor LY294002. Onco. Targets Ther. 8:877–883.

146. Rhim, A. D., P. E. Oberstein, D. H. Thomas, E. T. Mirek, C. F. Palermo, S. A. Sastra, et al. 2014. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25:735–747.

147. Lee, J. J., R. M. Perera, H. Wang, D.-C. Wu, X. S. Liu, S. Han, et al. 2014. Stromal response to Hedgehog signaling restrains pancreatic cancer progression. Proc. Natl Acad. Sci. USA 111:E3091–E3100.

148. Rodon, J., H. A. Tavabi, A. L. Thomas, R. G. Stoller, C. P. Turtschi, J. Baselga, et al. 2014. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors. Clin. Cancer Res. 20:1900–1909.

149. Goldman, J., S. G. Eckhardt, M. J. Borad, K. K. Curtis, M. Hidalgo, E. Calvo, et al. 2015. Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors. Clin. Cancer Res. 21:1002–1009.